+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody-drug Conjugate Therapeutics Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • PDF Icon

    Report

  • 100 Pages
  • November 2024
  • Region: Global
  • Prof Research
  • ID: 5726908
The Antibody-Drug Conjugate (ADC) therapeutics market has emerged as a leading frontier in oncology, showcasing innovative treatment modalities that enhance the specificity and efficacy of chemotherapeutic agents. ADCs consist of an antibody linked to a cytotoxic drug, allowing for targeted destruction of cancer cells while preserving healthy tissue. This technology has proven transformative in improving patient outcomes across multiple cancer types, driving extensive research and commercial interest into ADC development.

Market Size

The global Antibody-Drug Conjugates market was valued at approximately $4.2 billion in 2023 and is projected to reach around $9.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of about 14.7% during the forecast period. The increasing incidence of cancer globally, coupled with the growing popularity of personalized medicine and targeted therapies, has been a crucial factor in accelerating market growth.

Market Share & Trends Analysis

The Antibody-Drug Conjugate therapeutics market can be segmented by various factors including product type, key players, process, application, and region. This analysis breaks down the market into its intricate layers to provide a comprehensive understanding of its dynamics.

By Product Type

  • Gemtuzumab ozogamicin - Market share: 10% (2023)
  • Brentuximab vedotin - Market share: 15% (2023)
  • Trastuzumab emtansine - Market share: 20% (2023)
  • Inotuzumab ozogamicin - Market share: 5% (2023)
  • Polatuzumab vedotin - Market share: 7% (2023)
  • Enfortumab vedotin - Market share: 6% (2023)
  • Trastuzumab deruxtecan - Market share: 8% (2023)
  • Sacituzumab govitecan - Market share: 9% (2023)
  • Belantamab mafodotin - Market share: 3% (2023)
  • Moxetumomab pasudotox - Market share: 4% (2023)
  • Loncastuximab tesirine - Market share: 3% (2023)

By Key Players

The market is dominated by several key players, including:
  • ADC Therapeutics SA
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Daiichi Sankyo Company Ltd.
  • Genentech Inc.
  • Gilead Sciences
  • GlaxoSmithKline
  • Pfizer
  • Rakuten Medical Inc.
  • Seagen, Inc.

By Process

The ADC manufacturing process involves multiple steps including:
  • Antibody Development
  • Linker Optimization
  • Drug Conjugation
  • Purification & Characterization

By Application

ADCs are primarily applied in treating various types of cancers, including:
  • Breast Cancer
  • Leukemia
  • Lymphoma
  • Bladder Cancer

By End-Use

The end-users of ADC therapeutics are primarily:
  • Hospitals
  • Oncology Clinics
  • Research Institutions

By Region

The Antibody-Drug Conjugates market is divided into several regions:
  • North America - Major market due to high R&D activities and advanced healthcare infrastructure.
  • Europe - Increased adoption of targeted therapies and supportive regulations.
  • Asia-Pacific - Rapidly growing market with the rise of healthcare expenditure.
  • Latin America - Emerging market with rising incidences of cancer.
  • Middle East & Africa - Focus on developing healthcare infrastructure and cancer awareness.

Market News on Policy and Companies

Recent initiatives in the ADC market have been propelled by healthcare policies aimed at improving cancer treatment accessibility. Companies are continuously innovating to enhance ADC formulations, which has led to breakthroughs in treatment efficacy and reduction of side effects. Regulatory approvals for newer ADC products have accelerated in recent years, facilitating quicker market entry for these therapeutics. For example, recent approvals of Trastuzumab deruxtecan have showcased its potential in treating HER2-positive breast cancer, strengthening its market presence.

Segment Forecasts, 2024-2029

Looking forward, the Antibody-Drug Conjugates market is expected to continue its robust growth trajectory. Significant diet patterns, increased funding for cancer research, and the expansion of the therapeutic pipeline will each contribute to evolving market dynamics. Projected forecasts for the various segments of the market are as follows:

  • Product Type: The largest growth is anticipated in the Trastuzumab emtansine segment, owing to its established use in clinical settings.
  • Key Players: Companies like AstraZeneca and Genentech are poised to capture significant market shares due to their ongoing clinical trials and innovative ADC developments.
  • Applications: The focus on ADCs for breast cancer and lymphoma treatments is expected to drive demand significantly.
  • Regions: The Asia-Pacific region is projected to exhibit the highest growth, driven by increasing investments in healthcare expansion and research.

Conclusion

In conclusion, the Antibody-Drug Conjugate therapeutics market is positioned for significant growth as it responds to the pressing needs of an evolving oncology landscape. Advancements in ADC technology, supportive legislative frameworks, and the increasing prevalence of cancer are elements driving the market forward. As demands for more effective and less toxic cancer treatments mount, the ADC market stands at the forefront of the cancer therapeutics revolution, poised for remarkable developments over the coming years.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
5.6 COVID-19 Impact
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Antibody-Drug Conjugate Therapeutics Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Antibody-Drug Conjugate Therapeutics Market in North America (2019-2029)
8.1 Antibody-Drug Conjugate Therapeutics Market Size
8.2 Antibody-Drug Conjugate Therapeutics Market by End Use
8.3 Competition by Players/Suppliers
8.4 Antibody-Drug Conjugate Therapeutics Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Antibody-Drug Conjugate Therapeutics Market in South America (2019-2029)
9.1 Antibody-Drug Conjugate Therapeutics Market Size
9.2 Antibody-Drug Conjugate Therapeutics Market by End Use
9.3 Competition by Players/Suppliers
9.4 Antibody-Drug Conjugate Therapeutics Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Antibody-Drug Conjugate Therapeutics Market in Asia & Pacific (2019-2029)
10.1 Antibody-Drug Conjugate Therapeutics Market Size
10.2 Antibody-Drug Conjugate Therapeutics Market by End Use
10.3 Competition by Players/Suppliers
10.4 Antibody-Drug Conjugate Therapeutics Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Antibody-Drug Conjugate Therapeutics Market in Europe (2019-2029)
11.1 Antibody-Drug Conjugate Therapeutics Market Size
11.2 Antibody-Drug Conjugate Therapeutics Market by End Use
11.3 Competition by Players/Suppliers
11.4 Antibody-Drug Conjugate Therapeutics Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Antibody-Drug Conjugate Therapeutics Market in MEA (2019-2029)
12.1 Antibody-Drug Conjugate Therapeutics Market Size
12.2 Antibody-Drug Conjugate Therapeutics Market by End Use
12.3 Competition by Players/Suppliers
12.4 Antibody-Drug Conjugate Therapeutics Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Antibody-Drug Conjugate Therapeutics Market (2019-2024)
13.1 Antibody-Drug Conjugate Therapeutics Market Size
13.2 Antibody-Drug Conjugate Therapeutics Market by End Use
13.3 Competition by Players/Suppliers
13.4 Antibody-Drug Conjugate Therapeutics Market Size by Type
Chapter 14 Global Antibody-Drug Conjugate Therapeutics Market Forecast (2024-2029)
14.1 Antibody-Drug Conjugate Therapeutics Market Size Forecast
14.2 Antibody-Drug Conjugate Therapeutics Application Forecast
14.3 Competition by Players/Suppliers
14.4 Antibody-Drug Conjugate Therapeutics Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 ADC Therapeutics SA
15.1.1 Company Profile
15.1.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.1.3 SWOT Analysis of ADC Therapeutics SA
15.1.4 ADC Therapeutics SA Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.2 Astellas Pharma Inc.
15.2.1 Company Profile
15.2.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.2.3 SWOT Analysis of Astellas Pharma Inc.
15.2.4 Astellas Pharma Inc. Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.3 AstraZeneca plc
15.3.1 Company Profile
15.3.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.3.3 SWOT Analysis of AstraZeneca plc
15.3.4 AstraZeneca plc Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.4 Daiichi Sankyo Company Ltd.
15.4.1 Company Profile
15.4.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.4.3 SWOT Analysis of Daiichi Sankyo Company Ltd.
15.4.4 Daiichi Sankyo Company Ltd. Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.5 Genentech Inc.
15.5.1 Company Profile
15.5.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.5.3 SWOT Analysis of Genentech Inc.
15.5.4 Genentech Inc. Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.6 Gilead Sciences
15.6.1 Company Profile
15.6.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.6.3 SWOT Analysis of Gilead Sciences
15.6.4 Gilead Sciences Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.7 GlaxoSmithKline
15.7.1 Company Profile
15.7.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.7.3 SWOT Analysis of GlaxoSmithKline
15.7.4 GlaxoSmithKline Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.8 Pfizer
15.8.1 Company Profile
15.8.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.8.3 SWOT Analysis of Pfizer
15.8.4 Pfizer Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.9 Rakuten Medical Inc.
15.9.1 Company Profile
15.9.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.9.3 SWOT Analysis of Rakuten Medical Inc.
15.9.4 Rakuten Medical Inc. Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.10 Seagen
15.10.1 Company Profile
15.10.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.10.3 SWOT Analysis of Seagen
15.10.4 Seagen Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
15.11 Inc.
15.11.1 Company Profile
15.11.2 Main Business and Antibody-drug Conjugate Therapeutics Information
15.11.3 SWOT Analysis of Inc.
15.11.4 Inc. Antibody-drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Antibody-Drug Conjugate Therapeutics Report
Table Data Sources of Antibody-Drug Conjugate Therapeutics Report
Table Major Assumptions of Antibody-Drug Conjugate Therapeutics Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Antibody-Drug Conjugate Therapeutics Picture
Table Antibody-Drug Conjugate Therapeutics Classification
Table Antibody-Drug Conjugate Therapeutics Applications
Table Drivers of Antibody-Drug Conjugate Therapeutics Market
Table Restraints of Antibody-Drug Conjugate Therapeutics Market
Table Opportunities of Antibody-Drug Conjugate Therapeutics Market
Table Threats of Antibody-Drug Conjugate Therapeutics Market
Table COVID-19 Impact For Antibody-Drug Conjugate Therapeutics Market
Table Raw Materials Suppliers
Table Different Production Methods of Antibody-Drug Conjugate Therapeutics
Table Cost Structure Analysis of Antibody-Drug Conjugate Therapeutics
Table Key End Users
Table Latest News of Antibody-Drug Conjugate Therapeutics Market
Table Merger and Acquisition
Table Planned/Future Project of Antibody-Drug Conjugate Therapeutics Market
Table Policy of Antibody-Drug Conjugate Therapeutics Market
Table 2019-2029 North America Antibody-Drug Conjugate Therapeutics Market Size
Figure 2019-2029 North America Antibody-Drug Conjugate Therapeutics Market Size and CAGR
Table 2019-2029 North America Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2019-2024 North America Antibody-Drug Conjugate Therapeutics Key Players Revenue
Table 2019-2024 North America Antibody-Drug Conjugate Therapeutics Key Players Market Share
Table 2019-2029 North America Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2019-2029 United States Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Canada Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Mexico Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 South America Antibody-Drug Conjugate Therapeutics Market Size
Figure 2019-2029 South America Antibody-Drug Conjugate Therapeutics Market Size and CAGR
Table 2019-2029 South America Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2019-2024 South America Antibody-Drug Conjugate Therapeutics Key Players Revenue
Table 2019-2024 South America Antibody-Drug Conjugate Therapeutics Key Players Market Share
Table 2019-2029 South America Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2019-2029 Brazil Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Argentina Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Chile Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Peru Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Asia & Pacific Antibody-Drug Conjugate Therapeutics Market Size
Figure 2019-2029 Asia & Pacific Antibody-Drug Conjugate Therapeutics Market Size and CAGR
Table 2019-2029 Asia & Pacific Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2019-2024 Asia & Pacific Antibody-Drug Conjugate Therapeutics Key Players Revenue
Table 2019-2024 Asia & Pacific Antibody-Drug Conjugate Therapeutics Key Players Market Share
Table 2019-2029 Asia & Pacific Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2019-2029 China Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 India Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Japan Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 South Korea Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Southeast Asia Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Australia Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Europe Antibody-Drug Conjugate Therapeutics Market Size
Figure 2019-2029 Europe Antibody-Drug Conjugate Therapeutics Market Size and CAGR
Table 2019-2029 Europe Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2019-2024 Europe Antibody-Drug Conjugate Therapeutics Key Players Revenue
Table 2019-2024 Europe Antibody-Drug Conjugate Therapeutics Key Players Market Share
Table 2019-2029 Europe Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2019-2029 Germany Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 France Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 United Kingdom Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Italy Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Spain Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Belgium Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Netherlands Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Austria Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Poland Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Russia Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 MEA Antibody-Drug Conjugate Therapeutics Market Size
Figure 2019-2029 MEA Antibody-Drug Conjugate Therapeutics Market Size and CAGR
Table 2019-2029 MEA Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2019-2024 MEA Antibody-Drug Conjugate Therapeutics Key Players Revenue
Table 2019-2024 MEA Antibody-Drug Conjugate Therapeutics Key Players Market Share
Table 2019-2029 MEA Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2019-2029 Egypt Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Israel Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 South Africa Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Gulf Cooperation Council Countries Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2029 Turkey Antibody-Drug Conjugate Therapeutics Market Size
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Size by Region
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Size Share by Region
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Share by Application
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Key Vendors Revenue
Figure 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Size and Growth Rate
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Key Vendors Market Share
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2019-2024 Global Antibody-Drug Conjugate Therapeutics Market Share by Type
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Market Size by Region
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Market Size Share by Region
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Market Size by Application
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Market Share by Application
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Key Vendors Revenue
Figure 2024-2029 Global Antibody-Drug Conjugate Therapeutics Market Size and Growth Rate
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Key Vendors Market Share
Table 2024-2029 Global Antibody-Drug Conjugate Therapeutics Market Size by Type
Table 2024-2029 Antibody-Drug Conjugate Therapeutics Global Market Share by Type

Companies Mentioned

  • ADC Therapeutics SA
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Daiichi Sankyo Company Ltd.
  • Genentech Inc.
  • Gilead Sciences
  • GlaxoSmithKline
  • Pfizer
  • Rakuten Medical Inc.
  • Seagen Inc.